Turkey - Pharmaceutical Company for Sale

Outside the BRIC (Brazil, Russia, India, China) states, Turkey is considered one of the key growth pharmaceutical markets globally. Growth has been rapid in recent years, with per capita spending reaching US$159 in 2008, a similar level to other emerging countries in Eastern Europe. The country's large, ageing and increasingly urbanised population, means both demand and access to medicines should increase in the future. Over the next five years, sales of pharmaceuticals, which include prescription drugs and over-the-counter (OTC) medicines, will increase from US$11.3bn to US$19.5bn, representing a compound annual growth rate (CAGR) of 11.6%.

Despite positive market and environmental dynamics, Turkey ranks only fifth in the Pharmaceutical Business Environment Rankings for Q209. The core reasoning behind this is the still considerable risks present in operating in the country. A negative regulatory climate is a key drawback for multinationals. Delays in bringing products to market, unfavorable pricing regimes and poorly enforced intellectual property regulations are some of the problems associated with operating in Turkey at present. Furthermore, policy continuity, bureaucracy and the legal framework remain key considerations. Acquiring established local company is the usual way for minimizing of time constraints and other business risks. 

Farmavita.Net member is looking to sell established pharmaceutical business in Turkey

Compnay detils:

Annual turnover: 700.000 US$

Number of employees: 17

Property: complete building is rented, rent: 7.000 $/month

Production lines: Capsules, tablets, syrups, semisolid products (ointments, creams, gels)

Marketing Authorizations: Company is holder of 21 marketing authorizations for generic products. Please, contact us for detailed portfolio information!

Products under registration: Company has 25 generic products submitted for registration in Turkey.

Products in development: Company has 24 generic products different stages of development. Please, contact us for detailed portfolio information!

Short Company Profile
Before previous Turkish economic crisis, company used to be contract manufacturer to reputable pharmaceutical companies. Due to the crisis company have had financial difficulties and couldn't modernized the production machines. Therefore it has lost national GMP license. Volume of manufacture and sales has declined sharply in recent years.

Company management estimates that with 3 millions US$ of investments, GMP license could be obtained in few months. Expected company price is 3,0 millions US$.

For more details please contact:

Mr. Zdravko Mauko
CEO

Farmavita.Net - Pharmaceutical Licensing Network
www.farmavita.net

Farmavita d.o.o.
Okicka desni odvojak 2
HR-10430 Samobor
Hrvatska (Croatia)
Tel: +385-1-3377 058
Fax: +385-1-3360 785

• The Cardiovascular Market Outlook to 2015 (17/08/2010)
• Production of Study Medication for Nordic Markets (02/08/2010)
• Pharma Marketing 2010 (20/07/2010)

---